NCT06068439View on ClinicalTrials.gov

Study of the Protective Effect of Low-dose Aspirin on Renal Function in Patients With Early Diabetic Nephropathy

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

355

Participants

Timeline

Start Date

January 1, 2024

Primary Completion Date

January 30, 2027

Study Completion Date

June 30, 2027

Conditions

Diabetic Nephropathy Type 2

Interventions

DRUG

Acetylsalicylic Acid

aspirin 50 mg/d to be taken after dinner (in nonfasting conditions)

DRUG

Placebo

Placebo 50 mg/d to be taken after dinner (in nonfasting conditions)

All Listed Sponsors

lead

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER

NCT06068439 - Study of the Protective Effect of Low-dose Aspirin on Renal Function in Patients With Early Diabetic Nephropathy | Biotech Hunter | Biotech Hunter